Literature DB >> 21506995

Medial gastrocnemius muscle volume and fascicle length in children aged 2 to 5 years with cerebral palsy.

Lee Barber1, Tandy Hastings-Ison, Richard Baker, Rod Barrett, Glen Lichtwark.   

Abstract

AIM: The aim of this article was to compare medial gastrocnemius muscle volume, physiological cross-sectional area (PCSA), muscle length, fascicle length, and pennation angle in children aged 2 to 5 years with spastic cerebral palsy (CP) and in typically developing children. method: Fifteen children with spastic CP (11 males, four females; mean age 45 mo [SD 15 mo]; five with hemiplega; 10 with diplega; 10 classified at Gross Motor Function Classification System (GMFCS) level I, five at GMFCS level II) and 20 typically developing children (11 males, nine females; mean age 48 mo [SD 14 mo]) participated in the study. Individuals with spastic CP were included if they had a minimum range of motion of 0° ankle dorsiflexion with the knee extended and were excluded if they had had previous botulinum toxin treatment to the calf muscles or previous calf surgery. Typically developing children were included if they were able to walk independently and were excluded if there was a history of previous lower leg injury or other developmental disorder affecting the lower limb. Freehand two-dimensional and three-dimensional ultrasound was used to assess muscle properties of the relaxed medial gastrocnemius muscle at three ankle joint angles: maximum dorsiflexion, neutral and maximum plantarflexion. PCSA was calculated as a function of muscle volume and muscle fascicle length and pennation angle was recorded at the neutral ankle joint angle.
RESULTS: Medial gastrocnemius muscle volume was 22% lower in the group with spastic CP than in the typically developing group, which in the absence of significant group differences in neutral fascicle length gave rise to an equivalent reduction in PCSA for the group with spastic CP. Significant positive correlations were found between muscle volume and age (r=0.63-0.65) and between muscle length and age (r=0.72-0.81) in both groups. Maximum ankle dorsiflexion angle was also reduced in the group with spastic CP (8°) compared with the typically developing group (26°).
INTERPRETATION: The observed reduction in muscle PCSA in the group with spastic CP would be expected to contribute to the clinically observed muscle weakness in spastic CP and suggests the need for early intervention in order to minimize loss of muscle PCSA in spastic CP. © The Authors. Developmental Medicine & Child Neurology
© 2011 Mac Keith Press.

Entities:  

Mesh:

Year:  2011        PMID: 21506995     DOI: 10.1111/j.1469-8749.2011.03913.x

Source DB:  PubMed          Journal:  Dev Med Child Neurol        ISSN: 0012-1622            Impact factor:   5.449


  41 in total

1.  The effects of botulinum toxin injection frequency on calf muscle growth in young children with spastic cerebral palsy: a 12-month prospective study.

Authors:  Lee Barber; Tandy Hastings-Ison; Richard Baker; H Kerr Graham; Rod Barrett; Glen Lichtwark
Journal:  J Child Orthop       Date:  2013-06-18       Impact factor: 1.548

Review 2.  Pathophysiology of muscle contractures in cerebral palsy.

Authors:  Margie A Mathewson; Richard L Lieber
Journal:  Phys Med Rehabil Clin N Am       Date:  2015-02       Impact factor: 1.784

3.  Atypical triceps surae force and work patterns underlying gait in children with cerebral palsy.

Authors:  Anahid Ebrahimi; Michael H Schwartz; Jack A Martin; Tom F Novacheck; Darryl G Thelen
Journal:  J Orthop Res       Date:  2022-02-25       Impact factor: 3.102

Review 4.  Complicated Muscle-Bone Interactions in Children with Cerebral Palsy.

Authors:  Christopher M Modlesky; Chuan Zhang
Journal:  Curr Osteoporos Rep       Date:  2020-02       Impact factor: 5.096

5.  Loss of myogenic potential and fusion capacity of muscle stem cells isolated from contractured muscle in children with cerebral palsy.

Authors:  Andrea A Domenighetti; Margie A Mathewson; Rajeswari Pichika; Lydia A Sibley; Leyna Zhao; Henry G Chambers; Richard L Lieber
Journal:  Am J Physiol Cell Physiol       Date:  2018-04-25       Impact factor: 4.249

Review 6.  Are mechanically sensitive regulators involved in the function and (patho)physiology of cerebral palsy-related contractures?

Authors:  Jessica Pingel; Frank Suhr
Journal:  J Muscle Res Cell Motil       Date:  2017-11-30       Impact factor: 2.698

7.  Does a Reduced Number of Muscle Stem Cells Impair the Addition of Sarcomeres and Recovery from a Skeletal Muscle Contracture? A Transgenic Mouse Model.

Authors:  Sudarshan Dayanidhi; Matthew C Kinney; Peter B Dykstra; Richard L Lieber
Journal:  Clin Orthop Relat Res       Date:  2020-04       Impact factor: 4.755

8.  FAST CP: protocol of a randomised controlled trial of the efficacy of a 12-week combined Functional Anaerobic and Strength Training programme on muscle properties and mechanical gait deficiencies in adolescents and young adults with spastic-type cerebral palsy.

Authors:  Jarred G Gillett; Glen A Lichtwark; Roslyn N Boyd; Lee A Barber
Journal:  BMJ Open       Date:  2015-06-26       Impact factor: 2.692

9.  Assessment of net knee moment-angle characteristics by instrumented hand-held dynamometry in children with spastic cerebral palsy and typically developing children.

Authors:  Helga Haberfehlner; Huub Maas; Jaap Harlaar; Irene E Newsum; Jules G Becher; Annemieke I Buizer; Richard T Jaspers
Journal:  J Neuroeng Rehabil       Date:  2015-08-15       Impact factor: 4.262

10.  COpenhagen Neuroplastic TRaining Against Contractures in Toddlers (CONTRACT): protocol of an open-label randomised clinical trial with blinded assessment for prevention of contractures in infants with high risk of cerebral palsy.

Authors:  Maria Willerslev-Olsen; Jakob Lorentzen; Katrine Røhder; Anina Ritterband-Rosenbaum; Mikkel Justiniano; Andrea Guzzetta; Ane Vibeke Lando; Anne-Mette Bæk Jensen; Gorm Greisen; Sofie Ejlersen; Line Zacho Pedersen; Britta Andersen; Patricia Lipthay Behrend; Jens Bo Nielsen
Journal:  BMJ Open       Date:  2021-07-06       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.